Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods.
During the last decade there has been an unexpectedly rapid evolution of antimicrobial resistance in the respiratory pathogens for community- and hospital-acquired pneumonia. In order to choose the most optimal therapy for their patients, it is essential that physicians be aware of the prevalence and mechanisms of resistance and their implications on the effectiveness of the various antimicrobials.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.
D E
DE
Low
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004250:DNA Topoisomerases, Type II / Q000187:drug effects; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D005798:Genes, Bacterial / Q000187:drug effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006092:Gram-Negative Facultatively Anaerobic Rods / Q000187:drug effects*; D006801:Humans; D055231:Lincosamides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000187:drug effects; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics; D014769:Virginiamycin / Q000494:pharmacology; D018440:beta-Lactam Resistance / Q000502:physiology
D000900:Anti-Bacterial Agents; D055231:Lincosamides; D018942:Macrolides; D014769:Virginiamycin; D004250:DNA Topoisomerases, Type II